Open AccessPatient-reported outcomes from a phase IV study of aflibercept in patients with refractory retinal vein occlusions
Author(s) -
Kimberly Spooner,
Samantha FraserBell,
Thomas Hong,
Andrew Chang
Publication year - 2021
Publication title -
taiwan journal of ophthalmology
Language(s) - English
Resource type - Journals
eISSN - 2211-5072
pISSN - 2211-5056
DOI - 10.4103/tjo.tjo_19_20
Subject(s) - aflibercept , medicine , refractory (planetary science) , ranibizumab , retinal , ophthalmology , retinal vein , phase (matter) , surgery , bevacizumab , chemotherapy , physics , astrobiology , chemistry , organic chemistry
To determine the patient-centered effectiveness of switching patients with persistent macular edema due to retinal vein occlusion (RVO) to aflibercept using the National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ-25).